Abstract
BackgroundDactylitis and enthesitis are common debilitating manifestations of psoriatic arthritis (PsA).1 Secukinumab has previously been reported to reduce the number of dactylitic digits and enthesitis sites in patients (pts) with...
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have